- Home
- MYGN vs THQ Comparison
MYGN vs THQ Comparison
Compare MYGN & THQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- THQ
- Stock Information
- Founded
- MYGN 1991
- THQ 2014
- Country
- MYGN United States
- THQ United States
- Employees
- MYGN N/A
- THQ N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- THQ Finance Companies
- Sector
- MYGN Health Care
- THQ Finance
- Exchange
- MYGN Nasdaq
- THQ Nasdaq
- Market Cap
- MYGN 744.7M
- THQ 845.7M
- IPO Year
- MYGN 1995
- THQ N/A
- Fundamental
- Price
- MYGN $7.29
- THQ $18.70
- Analyst Decision
- MYGN Hold
- THQ
- Analyst Count
- MYGN 16
- THQ 0
- Target Price
- MYGN $20.17
- THQ N/A
- AVG Volume (30 Days)
- MYGN 1.2M
- THQ 158.9K
- Earning Date
- MYGN 05-06-2025
- THQ 01-01-0001
- Dividend Yield
- MYGN N/A
- THQ 7.53%
- EPS Growth
- MYGN N/A
- THQ N/A
- EPS
- MYGN N/A
- THQ N/A
- Revenue
- MYGN $837,600,000.00
- THQ N/A
- Revenue This Year
- MYGN $2.99
- THQ N/A
- Revenue Next Year
- MYGN $8.36
- THQ N/A
- P/E Ratio
- MYGN N/A
- THQ N/A
- Revenue Growth
- MYGN 11.21
- THQ N/A
- 52 Week Low
- MYGN $7.35
- THQ $15.29
- 52 Week High
- MYGN $29.30
- THQ $20.38
- Technical
- Relative Strength Index (RSI)
- MYGN 25.95
- THQ 40.83
- Support Level
- MYGN $7.69
- THQ $18.33
- Resistance Level
- MYGN $8.27
- THQ $19.50
- Average True Range (ATR)
- MYGN 0.56
- THQ 0.73
- MACD
- MYGN 0.02
- THQ -0.01
- Stochastic Oscillator
- MYGN 1.02
- THQ 41.56
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About THQ abrdn Healthcare Opportunities Fund Shares of Beneficial Interest
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. The fund's investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies.